Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 12 of 12 publications.

Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Citrome L, Sajatovic M. Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder. BMC Psychiatry. 2024 Sep 10;24(1):605. doi: 10.1186/s12888-024-06034-

Alatalo A, de Sousa Maciel I, Kucharikova N, Chew S, van Kamp I, Foraster M, Julvez J, Kanninen KM. The interaction between circulating cell-free mitochondrial DNA and inflammatory cytokines in predicting human mental health issue risk in adolescents: an explorative study. Biomedicines. 2023 Mar 7;11(3):818. doi: 10.3390/biomedicines11030818

Monsonet M, Rockwood NJ, Kwapil TR, Barrantes-Vidal N. Psychological pathways to paranoia and psychotic-like experiences in daily-life: the mediating role of distinct affective disturbances. Schizophr Bull. 2022 Sep 1;48(5):1053-65. doi: 10.1093/schbul/sbac071

Liu X, Miao H, Behrman JR, Hannum E, Liang Z, Zhao Q. The Asian Games, air pollution and birth outcomes in South China: an instrumental variable approach. Econ Hum Biol. 2022 Jan;44:101078. doi: 10.1016/j.ehb.2021.101078

Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med. 2021 May;9(5):e1664. doi: 10.1002/mgg3.1664

Carton-Garcia F, Saande CJ, Meraviglia-Crivelli D, Aldabe R, Pastor F. Oligonucleotide-based therapies for renal diseases. Biomedicines. 2021 Mar 16;9(3):303. doi: 10.3390/biomedicines9030303

Brain C, Kymes S, DiBenedetti DB, Brevig T, Velligan DI. Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study. BMC Psychiatry. 2018 Aug 13;18(1):253. doi: 10.1186/s12888-018-1833-5

Garland J, Stephen J, Class B, Gruber A, Ciccone C, Poliak A, Hayes CP, Singhal V, Slota C, Perreault J, Gavrilova R, Shrader JA, Chittiboina P, Joe G, Heiss J, Gahl WA, Huizing M, Carrillo N, Malicdan MCV. Identification of an Alu element-mediated deletion in the promoter region of GNE in siblings with GNE myopathy. Mol Genet Genomic Med. 2017 Jun 14;5(4):410-7. doi: 10.1002/mgg3.300

Llorca PM, Lancon C, Hartry A, Brown TM, DiBenedetti DB, Kamat SA, Francois C. Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications. BMC Psychiatry. 2017 Feb 13;17:67. doi: 10.1186/s12888-017-1213-6

Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. BMC Psychiatry. 2015 Aug 5;15:189. doi: 10.1186/s12888-015-0560-4.

Moragas L, Granero R, Stinchfield R, Fernandez-Aranda F, Froberg F, Aymami N, Gomez-Pena M, Fagundo AB, Islam MA, Del Pino-Gutierrez A, Aguera Z, Savvidou LG, Arcelus J, Witcomb GL, Sauchelli S, Menchon JM, Jimenez-Murcia S. Comparative analysis of distinct phenotypes in gambling disorder based on gambling preferences. BMC Psychiatry. 2015 Apr 15;15:86. doi: 10.1186/s12888-015-0459-0

Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry. 2013 Oct 5;13:246. doi: 10.1186/1471-244X-13-246.